OTC : ANPCF

Cellbxhealth PLC

$0.0199 USD

$0 (0.0%)

Volume
20K
Average Volume
4
Market Capitalization
$22.61M
P/E Ratio
Dividend Yield
%
Price Target
Year High
$0.11
Year Low
$0.01
Day High
—
Day Low
—
Payout Ratio
Current Ratio
Company Overview

OTC

Peter Michael Collins

Medical - Diagnostics & Research

Healthcare

ANPCF

119

GB

USD

https://cellbxhealth.com

44 14 8334 3434

N/A

0001620678

Liquidity Metrics

Sales & Valuation

$1.35M

Profitability

-$0.0551

-$19.51M

%

%

%

%

P/E Metrics

Analyst Price Target & Rating

Strong Sell

1/5

0 Analysts

%

Financial Health Scores

-31.18

2/9

$3.72M

$7.75M

$3.67M

-$17.18M

Key Metrics (TTM)

No key metrics data available.

Company Executives
Name Title
Lavanya Sivapalan Head of R&D
Cristina Ciccioli Head of Assay Development
Peter Michael Collins CEO & Director
Michelle Munson Chief of Staff
Sinéad Eithne Armstrong Finance Director & Secretary
Lauren Arthy-Miles ESG Lead
Poll Results

No votes yet today — be the first to share your view!

About Cellbxhealth PLC (OTC:ANPCF) Stock

CelLBxHealth plc, formerly known as ANGLE plc until its name change in October 2025, is a medical diagnostics enterprise established in 1994 and headquartered in Guildford, United Kingdom. The company is dedicated to developing advanced cancer diagnostic products, serving markets across the United Kingdom, Europe, North America, and other international regions. Its core offerings include the Parsortix PC1 and PR1 systems, which are innovative medical devices engineered to capture and retrieve intact circulating tumor cells (CTCs) from patient blood. Specifically, the PC1 system is designed for metastatic breast cancer samples, facilitating subsequent user-validated downstream analysis. CelLBxHealth also provides the Portrait+ CTC Staining kit, a laboratory solution for the identification, ... characterization, and enumeration of epithelial and mesenchymal CTCs with high analytical sensitivity and specificity, alongside the CellKeep Slide technology for CTC harvesting. In addition to these products, the company delivers a suite of laboratory services, including CTC enrichment and liquid biopsy analysis. Specialized assays are also available, such as Portrait Flex for immunofluorescence-based identification of epithelial, mesenchymal, and epithelial-to-mesenchymal transition, Portrait PD-L1 for CTC evaluation, and bespoke custom CTC assays. Furthermore, CelLBxHealth plc has forged strategic alliances, including a partnership with BioView Ltd to co-develop a human epidermal growth factor receptor 2 (HER2) assay kit for breast cancer, and an agreement with NuProbe USA, Inc. for the application of its pan-cancer next-generation sequencing (NGS) panel.

CelLBxHealth's blood test spots hard-to-detect cells from brain tumours

2026-08-12 02:38:26

An independent study has found that tumour cells circulating in the blood of patients with the most aggressive form of brain cancer can be captured and analysed using technology made by CelLBxHealth PLC (AIM:CLBX, FRA:DWV), the liquid biopsy company. Glioblastoma rarely spreads beyond the brain, which had made blood-based detection of the disease an unlikely prospect.

CelLBxHealth study detects drug targets on cancer cells rivals would miss

2026-08-03 02:31:28

CelLBxHealth PLC (AIM:CLBX, FRA:DWV), the liquid biopsy company, said an independent study had shown its Parsortix system can detect the biological targets used by a fast-growing class of cancer drugs on tumour cells captured from patients' blood. The peer-reviewed research, published in The Journal of Liquid Biopsy, was carried out by researchers at Trinity College Dublin and St James's Hospital, Dublin.

CelLBxHealth moves from cutting to converting

2026-07-15 04:56:13

The interim figures mark the point where CelLBxHealth PLC (AIM:CLBX, FRA:DWV) stops being a restructuring story and starts being a commercial one, says a note from Cavendish. The heavy lifting is done.

CelLBxHealth builds £3.5m weighted pipeline as revenue growth target held

2026-07-15 02:58:42

CelLBxHealth PLC (AIM:CLBX, FRA:DWV), the AIM-listed cancer diagnostics company, said its commercially weighted pipeline had built to £3.5 million, supported by rising engagement from pharmaceutical and diagnostic partners. It reiterated its forecast for revenue of at least £2.1 million for the 2026 financial year, growth of at least 50% on the prior year.

CelLBxHealth reaffirms revenue guidance

2026-07-14 02:54:43

CelLBxHealth PLC (AIM:CLBX, FRA:DWV), the cancer diagnostics company, has told shareholders it remains on track to deliver revenues of at least £2.1 million for 2026 as it searches for a new chief executive. The figure would represent a 50% increase on 2025.

Cavendish backs CelLBxHealth turnaround with buy rating, 4p target

2026-06-22 10:35:33

Cavendish remains bullish on CelLBxHealth PLC (AIM:CLBX, FRA:DWV) with a 'buy' rating and 4p price target in the wake of its prelims earlier. The AIM-listed biotech has completed a strategic reset centred on cost reduction and a shift towards partner-led commercialisation of its Parsortix platform.

CelLBxHealth guides for 50% revenue growth as partnership pipeline swells

2026-06-22 03:01:24

CelLBxHealth PLC (AIM:CLBX, FRA:DWV), the circulating tumour cell diagnostics company, expects revenues of at least £2.1 million in 2026, representing growth of at least 50% from last year's £1.4 million, underpinned by a commercial pipeline that has expanded 22% over the last quarter. The AIM-listed company has emerged from a year-long restructuring sharper and leaner, having cut its cost base substantially during 2025 and recruited new leadership to drive a partnership-focused strategy centred on pharmaceutical and diagnostic companies rather than research income.

CelLBxHealth strikes US clinical collaboration with AdventHealth cancer studies

2026-05-18 02:39:57

CelLBxHealth PLC (AIM:CLBX, FRA:DWV), the AIM-listed circulating tumour cell (CTC) diagnostics company, has secured a collaboration with AdventHealth, one of the largest faith-based health systems in the United States, to deploy its Parsortix platform in two clinical cancer studies. The trials, titled ACTION and SUNRISE, will use CelLBxHealth's technology to isolate and analyse CTCs from blood samples taken from patients undergoing treatment for colon, gastrointestinal and lung cancers.

Frequently Asked Questions

What is the current Cellbxhealth PLC (ANPCF) stock price?

Cellbxhealth PLC(OTC:ANPCF) stock price is $0.0199 in the last trading session. During the trading session, ANPCF stock reached the peak price of $0.10606 while $0.0103 was the lowest point it dropped to. The percentage change in ANPCF stock occurred in the recent session was 0.0% while the dollar amount for the price change in ANPCF stock was $0.

ANPCF's industry and sector of operation?

The OTC listed ANPCF is part of Medical - Diagnostics & Research industry that operates in the broader Healthcare sector.

Who are the executives of ANPCF?

Lavanya Sivapalan | Head of R&D
Cristina Ciccioli | Head of Assay Development
Peter Michael Collins | CEO & Director
Michelle Munson | Chief of Staff
Sinéad Eithne Armstrong | Finance Director & Secretary

How many employees does ANPCF have?

Number of ANPCF employees currently stands at 119. ANPCF operates from Surrey Research Park, Guildford, SU GU2 7AF, GB.

Link for ANPCF official website?

Official Website of ANPCF is: https://cellbxhealth.com

How do I contact ANPCF?

ANPCF could be contacted at phone #44 14 8334 3434 and can also be accessed through its website. ANPCF operates from Surrey Research Park, Guildford, SU GU2 7AF, GB.

How many shares of ANPCF are traded daily?

The average number of ANPCF shares traded daily for last 3 months was 4.

What is the market cap of ANPCF currently?

The market value of ANPCF currently stands at $22.61M with its latest stock price at $0.0199